Does the media favor OMCL or AMN?

In the previous week, Omnicell had 6 more articles in the media than AMN Healthcare Services. MarketBeat recorded 14 mentions for Omnicell and 8 mentions for AMN Healthcare Services. Omnicell's average media sentiment score of 0.94 beat AMN Healthcare Services' score of 0.91 indicating that Omnicell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AMN Healthcare Services 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer WST or OMCL?

In the previous week, West Pharmaceutical Services had 6 more articles in the media than Omnicell. MarketBeat recorded 20 mentions for West Pharmaceutical Services and 14 mentions for Omnicell. Omnicell's average media sentiment score of 0.94 beat West Pharmaceutical Services' score of 0.85 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment West Pharmaceutical Services 12 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omnicell 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HSTM or OMCL?

In the previous week, Omnicell had 10 more articles in the media than HealthStream. MarketBeat recorded 14 mentions for Omnicell and 4 mentions for HealthStream. Omnicell's average media sentiment score of 0.94 beat HealthStream's score of 0.56 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthStream 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omnicell 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer MDRX or OMCL?

Omnicell has a consensus target price of $59.86, suggesting a potential upside of 62.01%. Given Omnicell's stronger consensus rating and higher possible upside, analysts plainly believe Omnicell is more favorable than Veradigm. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradigm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Omnicell 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78

Which has preferable valuation & earnings, MDRX or OMCL?

Omnicell has lower revenue, but higher earnings than Veradigm. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradigm $1.53B 0.40 N/A N/A N/A Omnicell $1.18B 1.42 $2.05M $0.44 83.97

Is MDRX or OMCL more profitable?

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity. Company Net Margins Return on Equity Return on Assets Veradigm N/A N/A N/A Omnicell 1.67% 4.00% 2.46%

Does the media refer more to OMCL or HIMS?

In the previous week, Hims & Hers Health had 17 more articles in the media than Omnicell. MarketBeat recorded 31 mentions for Hims & Hers Health and 14 mentions for Omnicell. Omnicell's average media sentiment score of 0.94 beat Hims & Hers Health's score of 0.37 indicating that Omnicell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 8 Very Positive mention(s) 2 Positive mention(s) 12 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Neutral

Omnicell (OMCL) Competitors

$36.95 -4.45 (-10.76%)

As of 11:30 AM Eastern

Compare

OMCL vs. AMN, WST, HSTM, MDRX, and HIMS

Should you buy Omnicell stock or one of its competitors? MarketBeat compares Omnicell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Omnicell include AMN Healthcare Services (AMN), West Pharmaceutical Services (WST), HealthStream (HSTM), Veradigm (MDRX), and Hims & Hers Health (HIMS).

How does Omnicell compare to AMN Healthcare Services?

Omnicell (NASDAQ:OMCL) and AMN Healthcare Services (NYSE:AMN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Omnicell has higher earnings, but lower revenue than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.42	$2.05M	$0.44	83.97
AMN Healthcare Services	$2.73B	0.49	-$95.70M	-$0.87	N/A

In the previous week, Omnicell had 6 more articles in the media than AMN Healthcare Services. MarketBeat recorded 14 mentions for Omnicell and 8 mentions for AMN Healthcare Services. Omnicell's average media sentiment score of 0.94 beat AMN Healthcare Services' score of 0.91 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AMN Healthcare Services	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omnicell has a net margin of 1.67% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
AMN Healthcare Services	-0.95%	18.01%	5.19%

Omnicell presently has a consensus target price of $59.86, suggesting a potential upside of 62.01%. AMN Healthcare Services has a consensus target price of $29.00, suggesting a potential downside of 15.37%. Given Omnicell's stronger consensus rating and higher probable upside, equities research analysts plainly believe Omnicell is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are owned by institutional investors. 2.9% of Omnicell shares are owned by insiders. Comparatively, 1.1% of AMN Healthcare Services shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Omnicell has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

Summary

Omnicell beats AMN Healthcare Services on 12 of the 16 factors compared between the two stocks.

How does Omnicell compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

In the previous week, West Pharmaceutical Services had 6 more articles in the media than Omnicell. MarketBeat recorded 20 mentions for West Pharmaceutical Services and 14 mentions for Omnicell. Omnicell's average media sentiment score of 0.94 beat West Pharmaceutical Services' score of 0.85 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
West Pharmaceutical Services	12 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

West Pharmaceutical Services currently has a consensus price target of $364.42, indicating a potential upside of 8.34%. Omnicell has a consensus price target of $59.86, indicating a potential upside of 62.01%. Given Omnicell's higher probable upside, analysts clearly believe Omnicell is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
West Pharmaceutical Services	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

West Pharmaceutical Services has higher revenue and earnings than Omnicell. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
West Pharmaceutical Services	$3.07B	7.70	$493.70M	$7.81	43.07
Omnicell	$1.18B	1.42	$2.05M	$0.44	83.97

West Pharmaceutical Services has a net margin of 16.98% compared to Omnicell's net margin of 1.67%. West Pharmaceutical Services' return on equity of 20.11% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
West Pharmaceutical Services	16.98%	20.11%	14.83%
Omnicell	1.67%	4.00%	2.46%

West Pharmaceutical Services has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, Omnicell has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

93.9% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

West Pharmaceutical Services beats Omnicell on 12 of the 17 factors compared between the two stocks.

How does Omnicell compare to HealthStream?

HealthStream (NASDAQ:HSTM) and Omnicell (NASDAQ:OMCL) are both small-cap health care technology companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

HealthStream has a net margin of 6.39% compared to Omnicell's net margin of 1.67%. HealthStream's return on equity of 6.47% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthStream	6.39%	6.47%	4.44%
Omnicell	1.67%	4.00%	2.46%

HealthStream presently has a consensus target price of $27.00, suggesting a potential downside of 3.54%. Omnicell has a consensus target price of $59.86, suggesting a potential upside of 62.01%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than HealthStream.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

HealthStream has higher earnings, but lower revenue than Omnicell. HealthStream is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthStream	$304.06M	2.69	$18.34M	$0.67	41.78
Omnicell	$1.18B	1.42	$2.05M	$0.44	83.97

69.6% of HealthStream shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 20.4% of HealthStream shares are held by insiders. Comparatively, 2.9% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

HealthStream has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

In the previous week, Omnicell had 10 more articles in the media than HealthStream. MarketBeat recorded 14 mentions for Omnicell and 4 mentions for HealthStream. Omnicell's average media sentiment score of 0.94 beat HealthStream's score of 0.56 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthStream	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Omnicell beats HealthStream on 9 of the 16 factors compared between the two stocks.

How does Omnicell compare to Veradigm?

Veradigm (NASDAQ:MDRX) and Omnicell (NASDAQ:OMCL) are both small-cap health care technology companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Omnicell has a consensus target price of $59.86, suggesting a potential upside of 62.01%. Given Omnicell's stronger consensus rating and higher possible upside, analysts plainly believe Omnicell is more favorable than Veradigm.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Veradigm has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

In the previous week, Omnicell had 14 more articles in the media than Veradigm. MarketBeat recorded 14 mentions for Omnicell and 0 mentions for Veradigm. Omnicell's average media sentiment score of 0.94 beat Veradigm's score of 0.00 indicating that Omnicell is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradigm	Neutral
Omnicell	Positive

Omnicell has lower revenue, but higher earnings than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.40	N/A	N/A	N/A
Omnicell	$1.18B	1.42	$2.05M	$0.44	83.97

97.7% of Omnicell shares are owned by institutional investors. 2.3% of Veradigm shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Omnicell	1.67%	4.00%	2.46%

Summary

Omnicell beats Veradigm on 13 of the 14 factors compared between the two stocks.

How does Omnicell compare to Hims & Hers Health?

Omnicell (NASDAQ:OMCL) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Omnicell has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market.

Omnicell has a net margin of 1.67% compared to Hims & Hers Health's net margin of -0.56%. Hims & Hers Health's return on equity of 6.10% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
Hims & Hers Health	-0.56%	6.10%	1.52%

Omnicell currently has a consensus target price of $59.86, indicating a potential upside of 62.01%. Hims & Hers Health has a consensus target price of $31.43, indicating a potential upside of 18.84%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19

Hims & Hers Health has higher revenue and earnings than Omnicell. Hims & Hers Health is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.42	$2.05M	$0.44	83.97
Hims & Hers Health	$2.35B	2.61	$128.37M	-$0.09	N/A

97.7% of Omnicell shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 2.9% of Omnicell shares are held by insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Hims & Hers Health had 17 more articles in the media than Omnicell. MarketBeat recorded 31 mentions for Hims & Hers Health and 14 mentions for Omnicell. Omnicell's average media sentiment score of 0.94 beat Hims & Hers Health's score of 0.37 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	8 Very Positive mention(s)	2 Positive mention(s)	12 Neutral mention(s)	7 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Omnicell beats Hims & Hers Health on 9 of the 16 factors compared between the two stocks.

Get Omnicell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMCL vs. The Competition

Export

Metric	Omnicell	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.68B	$1.72B	$6.92B	$12.22B
Dividend Yield	N/A	N/A	2.65%	8.54%
P/E Ratio	83.96	73.33	27.51	23.52
Price / Sales	1.42	22.11	521.13	88.31
Price / Cash	15.56	26.22	51.57	59.34
Price / Book	1.35	5.53	10.13	5.81
Net Income	$2.05M	-$54.76M	$3.60B	$336.42M
7 Day Performance	-7.31%	-1.11%	-0.97%	-1.13%
1 Month Performance	-11.02%	-4.96%	-4.01%	-5.61%
1 Year Performance	24.40%	-5.22%	21.42%	15.59%

Omnicell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMCL Omnicell	2.814 of 5 stars	$36.95 -10.8%	$59.86 +62.0%	+39.8%	$1.68B	$1.18B	83.96	3,580	Trending News Gap Down
AMN AMN Healthcare Services	1.8189 of 5 stars	$33.72 -3.7%	$27.00 -19.9%	+78.0%	$1.36B	$2.73B	N/A	2,664	News Coverage Upcoming Earnings
WST West Pharmaceutical Services	3.5839 of 5 stars	$353.10 -1.4%	$363.17 +2.9%	+33.5%	$25.31B	$3.07B	47.21	10,800	Earnings Report Analyst Forecast
HSTM HealthStream	2.1183 of 5 stars	$28.33 -0.5%	$24.00 -15.3%	+11.3%	$832.05M	$304.06M	42.28	1,160	Upcoming Earnings
MDRX Veradigm	N/A	$4.80 +1.1%	N/A	+3.2%	$587.04M	$1.53B	23.25	8,000	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMCL) was last updated on 7/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omnicell (OMCL) Competitors

OMCL vs. AMN, WST, HSTM, MDRX, and HIMS

How does Omnicell compare to AMN Healthcare Services?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Summary

How does Omnicell compare to HealthStream?

Summary

How does Omnicell compare to Veradigm?

Summary

How does Omnicell compare to Hims & Hers Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omnicell (OMCL) Competitors

OMCL vs. AMN, WST, HSTM, MDRX, and HIMS

How does Omnicell compare to AMN Healthcare Services?

Which has higher valuation & earnings, OMCL or AMN?

Does the media favor OMCL or AMN?

Is OMCL or AMN more profitable?

Do analysts prefer OMCL or AMN?

Do institutionals and insiders have more ownership in OMCL or AMN?

Which has more risk & volatility, OMCL or AMN?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Does the media prefer WST or OMCL?

Do analysts recommend WST or OMCL?

Which has stronger earnings and valuation, WST or OMCL?

Is WST or OMCL more profitable?

Which has more risk & volatility, WST or OMCL?

Do institutionals & insiders believe in WST or OMCL?

Summary

How does Omnicell compare to HealthStream?

Is HSTM or OMCL more profitable?

Do analysts rate HSTM or OMCL?

Which has higher valuation & earnings, HSTM or OMCL?

Do institutionals & insiders have more ownership in HSTM or OMCL?

Which has more volatility & risk, HSTM or OMCL?

Does the media prefer HSTM or OMCL?

Summary

How does Omnicell compare to Veradigm?

Do analysts prefer MDRX or OMCL?

Which has more risk and volatility, MDRX or OMCL?

Does the media prefer MDRX or OMCL?

Which has preferable valuation & earnings, MDRX or OMCL?

Do institutionals & insiders have more ownership in MDRX or OMCL?

Is MDRX or OMCL more profitable?

Summary

How does Omnicell compare to Hims & Hers Health?

Which has more volatility & risk, OMCL or HIMS?

Is OMCL or HIMS more profitable?

Do analysts prefer OMCL or HIMS?

Which has preferable earnings and valuation, OMCL or HIMS?

Do insiders and institutionals believe in OMCL or HIMS?

Does the media refer more to OMCL or HIMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools